Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.67 +3.7% SGZ 0.040 −11.1% GRSL 0.310 −3.1% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.67 +3.7% SGZ 0.040 −11.1% GRSL 0.310 −3.1%
Other

Nextleaf Solutions Completes Initial Softgel Shipment to Australia and Announces Global Expansion of Commercial Partners Program(TM)

By The Northwire Desk — AI Analysis Feb 13, 2026 · 09:01 OILS · 0.045 Nextleaf Solutions Ltd.
OILS · Price

Executive Summary

  • Nextleaf Solutions announced the completion of an initial soft‑gel shipment of 756,000 cannabis softgels to a white‑label client in Australia, marking the first export under its Commercial Partners Program™.
  • The company highlighted global medical‑cannabis market growth (USD 39.6 bn in 2025 → USD 74.3 bn by 2034) and positioned itself as an export‑ready, pharma‑grade supplier with patented extraction technology.
  • CEO Emma Andrews will attend the Australian Medicinal Cannabis Association conference (Feb 26‑28, 2026) to meet potential partners and discuss expansion opportunities.

Key Details

  • Shipment: 756,000 cannabis softgels exported to Australia in January 2026; Nextleaf acted as exporter of record for a white‑label client.
  • Program Expansion: Commercial Partners Program™ launched to provide validated formulations, export‑ready infrastructure, and scalable operations for international partners.
  • Market Context: Global medical‑cannabis market valued at USD 39.6 bn in 2025; projected to reach USD 74.3 bn by 2034 (CAGR ≈ 6.9%).
  • Product Portfolio: Includes softgels, vapes, and oils under the Glacial Gold brand; emphasizes high‑purity, full‑spectrum cannabinoid ingredients and dose‑controlled delivery formats.
  • Patents & Capabilities: Holds 19 U.S. patents and over 75 global patents covering extraction, distillation, acetylation, and other advanced processes.
  • Conference Attendance: CEO Emma Andrews will attend the AMCA “United in Compassion” conference (Feb 26‑28, 2026, Brisbane) and is available for meetings in Sydney, Melbourne, and Brisbane. Contact via LinkedIn or [email protected].

Notable Quotes

“By leveraging our core capabilities, purchasing scale, lean infrastructure, and established regulatory expertise, Nextleaf streamlined the process and reinforced our role as a disciplined, capital‑efficient partner within the global medical cannabis supply chain.” – Vipin Vikraman, VP Operations

“Nextleaf is uniquely positioned to meet rising global demand through patented extraction technology and industry‑leading quality, setting the standard for processing cannabis at scale.” – Emma Andrews, CEO

Read the original news release →

More from Nextleaf Solutions Ltd.

Jun 01, 2026 · 09:31

Nextleaf Solutions Reports Q2 FY2026 Results, First International Export Revenue, Maintains 38% Gross Margin Amidst Pricing Compression

Earnings Apr 20, 2026 · 09:01

Nextleaf Solutions Confirms Capex-Light Expansion Strategy with New Micro-Processing Licence

Production / Operations Mar 04, 2026 · 00:49

Nextleaf Solutions earns $259,171 in fiscal Q1 2026

Earnings Mar 03, 2026 · 11:15

SEDAR Interim Financial Statements

None Mar 03, 2026 · 09:01

Nextleaf Solutions Reports Profitable Q1 FY26 with Revenue Growth and Positive Operating Cash Flow

Earnings Feb 20, 2026 · 04:07

Nextleaf appoints Kindred Canada as sales agency

Financings